677304-75-5

Basic information

• Product Name: 6-Bromo-1,2-benzisothiazole-3-carboxylic acid
• Synonyms: 6-bromobenzo[d]isothiazole-3-carboxylic acid;6-Bromo-1,2-benzisothiazole-3-carboxylic acid;6-Bromo-1,2-benzenisothiazole-carboxylic acid
• CAS NO: 677304-75-5
• Molecular Formula: C₈H₄BrNO₂S
• Molecular Weight: 258.09
• Mol File: 677304-75-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 337.5 °C at 760 mmHg
• Flash Point: 157.9 °C
• Appearance: /
• Density: 1.912
• Refractive Index: 1.753
• Storage Temp.: 2-8°C
• PKA: 4.69±0.50(Predicted)
• CAS DataBase Reference: 6-Bromo-1,2-benzisothiazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-1,2-benzisothiazole-3-carboxylic acid(677304-75-5)
• EPA Substance Registry System: 6-Bromo-1,2-benzisothiazole-3-carboxylic acid(677304-75-5)

Safety Data

• Hazardous Substances Data: 677304-75-5(Hazardous Substances Data)

Usage

General Description

6-Bromo-1,2-benzisothiazole-3-carboxylic acid is a chemical compound with the molecular formula C8H4BrNO2S. It falls under the category of organic compounds known as benzisothiazoles, which are aromatic heterocyclic compounds containing a benzene fused to an isothiazole ring. This chemical is typically solid and light-sensitive, often used in various chemical and pharmacological research. Its applications may include the development of pharmaceutical drugs and other chemical substances. However, the specific properties, reactivity, and safety measures for handling and storage should be referred to in the material safety data sheet (MSDS) provided by the manufacturer for proper use.

InChI:InChI=1/C8H4BrNO2S/c9-4-1-2-5-6(3-4)13-10-7(5)8(11)12/h1-3H,(H,11,12)

Upstream product

• 6320-01-0 3-Bromothiophenol 
• 947691-81-8 6-bromo-1,2-benzothiazole-3-carboxamide 

Downstream Products

• 858671-74-6 ethyl 6-bromobenzo[d]isothiazole-3-carboxylate 
• 932702-07-3 tert-butyl 6-bromo-benzo[d]isothiazole-3-carboxylate 

Relevant articles and documents

5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).

CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS

The present invention is directed to cinnoline and quinazoline compounds of formula (I) that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like.

1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of -disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.